Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

Oxysterol Receptor (GPR183) Antibodies

Close filters
No results were found for the filter!
NEW
Agonist-induced Threoine347/Serine349 phosphorylation of GPR183
pT347/pT349-GPR183 (phospho-GPR183 Antibody)
Threonine347/Threonine349 (T347/T349) is major phosphorylation site of human GPR183 receptor. The pT347/pT349-GPR183 antibody detects phosphorylation in response to agonists. T347/T349 phosphorylation is likely to be involved in...
$ 400.00 *
Details
NEW
Agonist-induced Serine355 phosphorylation of GPR183
pS355-GPR183 (phospho-GPR183 Antibody)
Serine355 (S355) is major phosphorylation site of human GPR183 receptor. The pS355-GPR183 antibody detects phosphorylation in response to agonists. S355 phosphorylation is likely to be involved in efficient ligand sequestration by GPR183.
$ 400.00 *
Details
NEW
Agonist-induced Serine343 phosphorylation of GPR183
pS343-GPR183 (phospho-GPR183 Antibody)
Serine343 (S343) is major phosphorylation site of human GPR183 receptor. The pS343-GPR183 antibody detects phosphorylation in response to agonists. S343 phosphorylation is likely to be involved in efficient ligand sequestration by GPR183.
$ 400.00 *
Details
NEW
Indentification of GPR183 Receptor in mouse tissues
GPR183 (GP-non-phospho), Oxysterol Receptor...
The non-phospho-GPR183 receptor antibody is directed against the distal end of the carboxyl-terminal tail of human GPR183. It also detects GPR183 in cultured cells and tissue sections by immunohistochemistry. It can be used to detect...
$ 400.00 *
Details
NEW
Immunohistochemical identification of GPR183 Receptor in human spleen
GPR183 (IHC-grade), Oxysterol Receptor Antibody
The non-phospho-GPR183 receptor antibody is directed against the distal end of the carboxyl-terminal tail of human GPR183. It also detects GPR183 in cultured cells and tissue sections by immunohistochemistry. It can be used to detect...
$ 400.00 *
Details
NEW
Validation of the GPR183 Receptor in transfected HEK293 cells
GPR183 (non-phospho), Oxysterol Receptor Antibody
The non-phospho-GPR183 receptor antibody is directed against the distal end of the carboxyl-terminal tail of human GPR183. It also detects GPR183 in cultured cells and tissue sections by immunohistochemistry. It can be used to detect...
$ 400.00 *
Details

GPR183 is a receptor for oxysterols. The most potent activator is 7α,25-dihydroxycholesterol (7α,25-OHC), with other oxysterols exhibiting varying affinities for the receptor. Oxysterol gradients drive chemotaxis, attracting the GPR183-expressing cells to locations of high ligand concentration. GPR183 is expressed on the surface of immune cells, namely B cells and T cells. Blocking the synthesis of 7α,25-OHC in vivo with clotrimazole, a CYP7B1 inhibitor, reduced the content of 7α,25-OHC in the mouse spleen and promoted the migration of adoptively transferred pre-activated B cells to the boundary between the T-zone and B-zone in the spleen follicle, mimicking the phenotype of pre-activated B cells from GPR183-deficient mice. Germinal central B cell differentiation is associated with downregulation of GPR183. GPR183-deficient mice show a reduction in the early antibody response to a T-dependent antigen. GPR183-deficient B cells fail to migrate to the outer follicle and instead stay in the follicle centre. This is suggested to position B cells in the correct location for mounting T-dependent antibody responses. GPR183 is induced during Epstein-Barr virus infection. It is also reported that GPR183 was significantly overexpressed in the metastatic sites (subcutis, regional lymph node and brain). For more information on GPR183 pharmacology please refer to the IUPHAR database. For further reading refer to:

Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, Pin JP, Spedding M, Harmar AJ. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev. 2013 May 17;65(3):967-86. doi: 10.1124/pr.112.007179. PMID: 23686350; PMCID: PMC3698937.

Alexander SP, Battey J, Benson HE, Benya RV, Bonner TI, Davenport AP, Dhanachandra Singh K, Eguchi S, Harmar A, Holliday N, Jensen RT, Karnik S, Kostenis E, Liew WC, Monaghan AE, Mpamhanga C, Neubig R, Pawson AJ, Pin JP, Sharman JL, Spedding M, Spindel E, Stoddart L, Storjohann L, Thomas WG, Tirupula K, Vanderheyden P. Class A Orphans in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1). Available from: https://doi.org/10.2218/gtopdb/F16/2023.1.

GPR183 is a receptor for oxysterols. The most potent activator is 7α,25-dihydroxycholesterol (7α,25-OHC), with other oxysterols exhibiting varying affinities for the receptor. Oxysterol... read more »
Close window
Oxysterol Receptor (GPR183) Antibodies

GPR183 is a receptor for oxysterols. The most potent activator is 7α,25-dihydroxycholesterol (7α,25-OHC), with other oxysterols exhibiting varying affinities for the receptor. Oxysterol gradients drive chemotaxis, attracting the GPR183-expressing cells to locations of high ligand concentration. GPR183 is expressed on the surface of immune cells, namely B cells and T cells. Blocking the synthesis of 7α,25-OHC in vivo with clotrimazole, a CYP7B1 inhibitor, reduced the content of 7α,25-OHC in the mouse spleen and promoted the migration of adoptively transferred pre-activated B cells to the boundary between the T-zone and B-zone in the spleen follicle, mimicking the phenotype of pre-activated B cells from GPR183-deficient mice. Germinal central B cell differentiation is associated with downregulation of GPR183. GPR183-deficient mice show a reduction in the early antibody response to a T-dependent antigen. GPR183-deficient B cells fail to migrate to the outer follicle and instead stay in the follicle centre. This is suggested to position B cells in the correct location for mounting T-dependent antibody responses. GPR183 is induced during Epstein-Barr virus infection. It is also reported that GPR183 was significantly overexpressed in the metastatic sites (subcutis, regional lymph node and brain). For more information on GPR183 pharmacology please refer to the IUPHAR database. For further reading refer to:

Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, Pin JP, Spedding M, Harmar AJ. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev. 2013 May 17;65(3):967-86. doi: 10.1124/pr.112.007179. PMID: 23686350; PMCID: PMC3698937.

Alexander SP, Battey J, Benson HE, Benya RV, Bonner TI, Davenport AP, Dhanachandra Singh K, Eguchi S, Harmar A, Holliday N, Jensen RT, Karnik S, Kostenis E, Liew WC, Monaghan AE, Mpamhanga C, Neubig R, Pawson AJ, Pin JP, Sharman JL, Spedding M, Spindel E, Stoddart L, Storjohann L, Thomas WG, Tirupula K, Vanderheyden P. Class A Orphans in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1). Available from: https://doi.org/10.2218/gtopdb/F16/2023.1.

Recently viewed